Anti-tumor activity of BDTX-1535, an irreversible CNS penetrant inhibitor of multiple EGFR extracellular domain alterations, in preclinical glioblastoma models. (October 2022) - Lucas, M.; Merchant, M.; O'Connor, M.; Smith, S.; Trombino, A.; Waters, N.; Eathiraj, S.; Ball, J.; Breschi, A.; Igartua, K.; Kang, M.; Buck, E.